About Us

Contact Us

Global Headquarters
Schering-Plough Corporation World Headquarters
2000 Galloping Hill Road
Kenilworth, N.J. 07033-0530
United States

Telephone: +1 (908) 298-4000

Directions to our New Jersey locations

Partnerships

In today's competitive pharmaceutical industry, strategic licensing agreements and partnerships are key to maintaining a balanced portfolio of products and technologies. To partner with us, please contact a representative in one of the following areas:

Human PrescriptionConsumer Health Care
Animal HealthMergers & Acquisitions


Growing Stronger, Growing Better

Read more about the combination...

Our combination with Organon BioSciences is a transformational step on Schering-Plough’s continuing journey as we build a high-performance company for the long term.



Read more about the combination...

Basic Facts & Figures

World Headquarters
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530

Chairman and CEO
Fred Hassan

Number of employees
51,000

Net sales (2008)
$18.5 billion

Business Operations in
more than 140 countries

Largest-selling products
VYTORIN*, ZETIA*, REMICADE, NASONEX, TEMODAR

R&D investment (2008)
$3.5 billion

Areas of research
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health

*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $4.5 billion in 2008.

Speeches & Presentations

The statements made in these speeches may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 about Schering-Plough's business and prospects. Actual results may differ materially from these forward-looking statements. Schering-Plough does not assume the obligation to update any forward-looking statements. For further details about risks and uncertainties that may affect forward-looking statements, see Schering-Plough's SEC filings, including Part I, Item 1A. Risk Factors, in the Company's third quarter 2008 10-Q and risk factors contained in future SEC filings.

DateDescription
8 October 2008CEO Hassan Delivers Keynote Speech at Intellectual Property Summit
2 November 2007A Four-Pronged Approach To Improving Current Health Care Environment
19 March 2007New Challenges, New Opportunities: Building a New Kind of Health Care Company”
10 November 2006Improving Cardiovascular Care: A Noble Mission